Lung mesenchymal stromal cells in development and disease: to serve and protect?

Area of Science:

• Neonatal medicine
• Pulmonary medicine
• Regenerative medicine

Background:

• Bronchopulmonary dysplasia (BPD) is a chronic lung disease affecting extremely preterm infants.
• Mesenchymal stromal cells (MSCs) show promise for treating neonatal and adult lung diseases.
• Each organ, including the lung, possesses its own reservoir of endogenous MSCs.

Purpose of the Study:

• To investigate the role and function of endogenous lung MSCs in lung development.
• To understand the behavior of lung MSCs in BPD, where alveolar development is impaired.
• To explore why bone marrow and umbilical cord MSCs may succeed where lung MSCs do not in restoring alveolar development.

Main Methods:

• The study discusses the current limited understanding of resident lung MSCs.
• It poses critical questions regarding the function of lung MSCs in BPD.
• It highlights the need for further research into endogenous lung MSCs.

Main Results:

• The exact nature and function of resident lung MSCs remain largely unknown.
• The mechanisms by which lung MSCs behave in the context of abnormal alveolar development in BPD are unclear.
• The comparative efficacy of endogenous lung MSCs versus allogeneic MSCs (from bone marrow/umbilical cord) in BPD treatment is not well understood.

Conclusions:

• Significant research is needed to fully characterize and validate lung MSCs.
• Understanding endogenous lung MSCs is crucial for developing effective MSC-based therapies for BPD.
• MSC-based treatments hold high potential for improving outcomes in BPD and other lung diseases.